Surrogate endpoints are indirect measures used in clinical trials to predict real clinical outcomes, such as survival or quality of life. In the context of cancer, common surrogate endpoints include tumor shrinkage, progression-free survival, or biomarker levels. These endpoints allow for quicker assessments of a drug's efficacy, facilitating earlier approval and access for patients in need.
